XFOR - X4 Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

XFOR is currently covered by 5 analysts with an average price target of $9.91. This is a potential upside of $6.57 (196.71%) from yesterday's end of day stock price of $3.34.

X4 Pharmaceuticals's activity chart (see below) currently has 12 price targets and 29 ratings on display. The stock rating distribution of XFOR is 86.67% BUY and 13.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 58.06% with an average time for these price targets to be met of 331.6 days.

Highest price target for XFOR is $7, Lowest price target is $0.5, average price target is $3.63.

Most recent stock forecast was given by SWAYAMPAKULA RAMAKANTH from HC WAINWRIGHT on 01-May-2025. First documented stock forecast 10-Dec-2017.

Currently out of the existing stock ratings of XFOR, 13 are a BUY (86.67%), 2 are a HOLD (13.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7

$3.63 (107.72%)

$1.5

11 days ago
(01-May-2025)

8/9 (88.89%)

$3.27 (87.67%)

378

Buy

$3

$-0.37 (-10.98%)

$5

1 months 17 days ago
(25-Mar-2025)

4/4 (100%)

$2.73 (1011.11%)

498

Hold

$0.5

$-2.87 (-85.16%)

$1

5 months 25 days ago
(17-Nov-2024)

2/2 (100%)

$0.13 (35.14%)

42

Buy

$5

5 months 29 days ago
(13-Nov-2024)

1/2 (50%)

$2.8 (127.27%)

712

Buy

$4

$0.63 (18.69%)

$3

1 years 11 months 26 days ago
(16-May-2023)

2/2 (100%)

$1.8 (81.82%)

731

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is XFOR (X4 Pharmaceuticals) average time for price targets to be met?

On average it took 331.6 days on average for the stock forecasts to be realized with a an average price target met ratio 58.06

Which analyst has the current highest performing score on XFOR (X4 Pharmaceuticals) with a proven track record?

KRISTEN KLUSKA

Which analyst has the most public recommendations on XFOR (X4 Pharmaceuticals)?

Kristen Kluska works at CANTOR FITZGERALD and has 5 price targets and 4 ratings on XFOR

Which analyst is the currently most bullish on XFOR (X4 Pharmaceuticals)?

Zegbeh Jallah with highest potential upside - $25.99

Which analyst is the currently most reserved on XFOR (X4 Pharmaceuticals)?

Kalpit Patel with lowest potential downside - -$2.87

X4 Pharmaceuticals in the News

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?